World Health Assembly Concludes With Actions On Range Of Issues 27/05/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment The 68th World Health Assembly (WHA), which took place from 18-26 May, was characterised as one of the most successful annual assemblies ever by Margaret Chan, World Health Organization director general. From the standpoint of intellectual property, access and innovation, this may be debatable. Below is a guide to the main accomplishments highlighted by Intellectual Property Watch. These include: action plans to fight antibiotic resistance and to boost vaccinations, extension of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA), incremental progress on alternative research and development for neglected diseases, status of the pandemic influenza preparedness framework, response to emergencies like Ebola, and WHO’s relationship with lobbyists and donors.
WHO Engagement With Non-State Actors: No Deal This Year, Work To Continue 26/05/2015 by Catherine Saez and William New, Intellectual Property Watch Leave a Comment The annual World Health Assembly closed today following a decision to postpone for one year completion of a new policy on the UN agency’s engagement with industry, foundations and other “non-state actors.”
WHA 68: Experts Discuss Delinking R&D Costs From Pricing To Make Medicines Affordable 25/05/2015 by William New, Intellectual Property Watch 1 Comment The problem of drug prices eating up national health budgets has been coming up at the annual World Health Assembly. Last week, a panel of experts discussed the merits of lowering those prices by delinking research and development costs from pricing.
Two UN Agencies Come Out In Support Of Extension Of TRIPS LDC Waiver 22/05/2015 by Catherine Saez, Intellectual Property Watch 5 Comments The United Nations Development Programme and the Joint UN Programme on HIV/AIDS have issued a joint statement supporting a request by least-developed countries to extend a waiver allowing them to abstain from enforcing patents on pharmaceutical products.
Five Challenges Filed Against Gilead Patent Claims For Hepatitis C Drug 20/05/2015 by Intellectual Property Watch Leave a Comment Pharmaceutical company Gilead Sciences has been noted first for developing a treatment for hepatitis C, which afflicts tens of millions around the world, and then for pricing it at jaw-dropping prices ($1000 per pill) in the United States and elsewhere. Now a group of health advocates has challenged Gilead’s patent applications in five emerging economies.
Did The WHO Just Invite Corporates To Set Health Policy? 20/05/2015 by Intellectual Property Watch, Intellectual Property Watch 1 Comment From the New Minute: The Director General of the World Health Organisation (WHO) Dr. Margaret Chan has invited the private sector, civil society and academia among others, to join a dialogue on how non-state players can work with the global body to enhance public health work. A leading voice in this configuration is the United States-based Global Health Council (GHC) whose strong and spirited response to the invitation has set the cat among the pigeons in some countries (including reportedly with India) and certain sections of non-governmental organisations (NGOs).
At WIPO Event, Music Creators Tell Of Desperate Economic Times 08/05/2015 by William New, Intellectual Property Watch 1 Comment NEW YORK – Musicians, songwriters, and producers recently gathered at a World Intellectual Property Organization event here and gave a stark depiction of a broken system that is not working for them financially, putting the very future of music-making at risk.
United States Hopeful Lisbon Members Will Open Diplomatic Conference To All 07/05/2015 by Catherine Saez, Intellectual Property Watch 2 Comments During a press briefing today the United States said they still have hope that the 28 members of a World Intellectual Property Organization-administered treaty will let the whole WIPO membership participate in next week’s negotiations to amend that treaty. It said that the potential new treaty protecting appellations of origins and set to include geographical indications can impact the economies of many non-member countries.
Industry Asks For Clarity On LDC Request To Extend TRIPS Pharma Waiver 01/05/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment Least developed countries (LDCs) at the World Trade Organization have requested that a waiver allowing them to not enforce intellectual property rights on pharmaceutical products be extended beyond its deadline of 1 January 2016. The brand pharmaceutical industry this week stated that it supports access to medicines for LDCs but does not see the need for this extension as LDCs already benefit from a WTO waiver on all products until 2021.
Pharma Offers View On How To Slow Antimicrobial Resistance, Boost Research 30/04/2015 by Catherine Saez, Intellectual Property Watch 1 Comment the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) provided its recommendations on how to slow down antimicrobial resistance and boost antibiotic research and development. In addition, the association organised a forum on the subject today.